MGMT and neoplasm: Analysis (Table 4) demonstrated that elevation of E2F7 was significantly linked with patient age (≤50 vs > 50, OR = 0.183, 95% CI (0.118‐0.284), P < .001), tumor grade (IV vs III, OR = 12.792, 95% CI (7.631‐21.444), P < .001), mutation status of IDH (WT vs mutant, OR = 29.639, 95% CI (17.111‐51.342), P < .001), and methylation status of MGMT promoter (methylation vs unmethylation, OR = 0.126, 95% CI (0.073‐0.215), P < .001).